About PALSONIFY
PALSONIFY delivers results that start strong and stay strong
Switching medication? New to medication or getting back on track? No matter where you are, PALSONIFY provides reliable acromegaly control.
David, musician,
living with acromegaly
PALSONIFY clinical study results
In a 24-week clinical study with 111 adults who were new to medication or restarting after a break, PALSONIFY helped:
Improve symptoms and quickly lower IGF-1
Reach treatment goals
56% of people taking PALSONIFY got their IGF-1 level down to normal, compared with just 5% of those who didn’t take PALSONIFY.
of people taking PALSONIFY experienced reductions in their IGF-1 levels
Get control fast
PALSONIFY helped reduce
- †ULN=upper limit of normal. This number marks the cutoff at the top of the normal range for
IGF-1 levels on a lab test. KeepingIGF-1 levels below 1.3x the ULN is an important goal of acromegaly treatment.
The most common PALSONIFY side effects were diarrhea (33%), stomach pain or discomfort (19%), nausea (9%), slow heart rate (bradycardia) (7%), and high blood sugar (7%).
IGF-1=insulin-like growth factor 1.
In a 36-week study with 58 adults who were switching from injections, PALSONIFY helped:
Maintain symptom and IGF-1 control—without interruption
Improve symptoms
People taking PALSONIFY experienced a reduction in the severity of common acromegaly symptoms—based on results from a symptom-tracking tool developed following FDA guidance called the .
People taking PALSONIFY also experienced fewer symptom flare-ups and more consistent symptom control.*
*Results are based on an additional analysis of the study. The number of days with symptom flare-ups decreased from 30.2% at baseline to 6.2% at week 36 of the study. Symptoms were assessed using the ASD.
Maintain progress
83% of people taking PALSONIFY maintained normal
Throughout the study: On average, IGF-1 levels stayed within the normal range for people taking PALSONIFY
- †ULN=upper limit of normal. This number marks the cutoff at the top of the normal range for
IGF-1 levels on a lab test. KeepingIGF-1 levels below 1.3x the ULN is an important goal of acromegaly treatment.
Stay in control
of people taking PALSONIFY who had normal IGF-1 levels at the end of the study were still in control over a year later‡
The most common PALSONIFY side effects were diarrhea (23%), nausea (13%), loss of appetite (10%), irregular heart beat (palpitations) (7%), and stomach bug–like symptoms (gastroenteritis) (7%).
- ‡Among people who achieved normal IGF-1 levels at week 36 in the study and completed the week-60 visit of the long-term follow-up study, 22 of 23 (96%) maintained normal IGF-1 levels at
week 60. - IGF-1=insulin-like growth factor 1.
Ask your healthcare team about PALSONIFY
Use this
Patricia, writer,
living with acromegalyThe Acromegaly Symptom Diary (ASD)
The ASD was developed for PALSONIFY clinical trials following guidance from the US Food and Drug Administration (FDA). It’s a tool created to better understand changes in common symptoms of acromegaly—beyond what lab tests can show.
In the PALSONIFY clinical trials, study participants filled out the ASD every day by rating the following symptoms. Each symptom was scored on a scale from 0 (no symptom) to 10 (worst imaginable). This helped researchers track how symptoms changed over time.